Form 4: Anika Therapeutics CEO Increases Stake in Company

President and CEO Stephen D. Griffin purchased 12,200 shares of Anika Therapeutics common stock on April 30, 2026.

Summary

• Stephen D. Griffin, President and CEO of Anika Therapeutics, acquired 12,200 shares of common stock.
• The shares were purchased at a weighted average price of $12.2853 per share.
• The transaction occurred on April 30, 2026.
• Following this transaction, the reporting person's total beneficial ownership increased to 36,163 shares.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive indicator of management confidence, as the CEO is using personal capital to increase his stake in the company.

Positives

• Insider confidence is demonstrated by the CEO's decision to increase his personal equity stake in the company.
• The purchase was made at market prices, signaling management's belief in the current valuation of the stock.

Negatives

• None identified in this filing.

Risks

• Market volatility affecting the value of the acquired shares.
• General risks associated with the medical device and biotechnology industry.

Future Outlook

Not applicable as this is a transaction disclosure filing.

Industry Context

StockSavvy.ai notes that insider buying by a CEO is generally viewed as a positive signal by the market, suggesting that leadership is aligned with shareholder interests and optimistic about the company's long-term prospects.

Comparison to Industry Standards

• Insider buying is a common practice among executives in the medical technology sector to signal confidence during periods of market fluctuation.

Stakeholder Impact

• Shareholders may view this as a positive signal of management's commitment to the company's future.

Next Steps

• No further actions required by the reporting person regarding this specific transaction.

Key Dates

Keywords

Anika Therapeutics, ANIK, Insider Trading, Form 4, Stephen D. Griffin, Equity Ownership